Mirtazapine

Introduction Overview

Generic Name

mirtazapine

Brand Name

Remeron, Remeron SolTab

Dosage Form

Oral tablets and orally disintegrating tablets

Drug Class

Tetracyclic antidepressants

Pharmacokinetics

Absorption:
Mirtazapine is well-absorbed orally with peak plasma concentrations typically reached within 2 hours post-administration. Its bioavailability is high and not significantly affected by food. The orally disintegrating tablet is designed for ease of administration but does not alter the overall absorption characteristics compared to standard tablets. Food intake does not markedly affect the rate or extent of absorption, offering flexibility in dosing times relative to meals.

Distribution:
The drug exhibits extensive distribution throughout the body, with an apparent volume of distribution ranging from approximately 1.5 to 2 L/kg. Mirtazapine is about 85% bound to plasma proteins, primarily albumin, which can be clinically relevant in patients with hypoalbuminemia or other conditions influencing protein binding. It crosses the blood-brain barrier effectively, consistent with its central nervous system target effects. The drug is also known to penetrate peripheral tissues moderately.

Metabolism:
Mirtazapine undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes including CYP1A2, CYP2D6, and CYP3A4. The metabolic pathways include demethylation, hydroxylation, and subsequent conjugation reactions, producing several metabolites, the majority of which are pharmacologically inactive. The metabolic rate can be influenced by co-administered drugs that modulate these CYP enzymes, leading to potential alterations in mirtazapine plasma levels. Genetic polymorphisms affecting CYP2D6 can also contribute to interindividual variability in metabolism.

Elimination:
Mirtazapine and its metabolites are primarily excreted renally, with approximately 75% of an administered dose recovered in urine mainly as metabolites, and around 15% eliminated via feces. The elimination half-life averages between 20 to 40 hours, allowing for once-daily dosing. Steady-state concentrations are typically reached within one week. Renal or hepatic impairment may influence elimination kinetics, necessitating careful monitoring or dose adjustments. No significant accumulation has been observed with regular dosing in patients with normal organ function.

Dosage Forms

Available Dosage Forms:
Mirtazapine is available primarily in two oral dosage forms:
- Oral tablet: available in strengths of 7.5 mg, 15 mg, 30 mg, and 45 mg
- Orally disintegrating tablet (Remeron SolTab): available in doses of 15 mg, 30 mg, and 45 mg

Dosages for Adults and Adolescents:
For the treatment of major depressive disorder in adults, the usual initial dose is 15 mg orally once daily at bedtime. The maintenance dose ranges from 15 mg to 45 mg once daily. Dosage may be increased every 1 to 2 weeks based on patient response and tolerability, with a maximum recommended dose of 45 mg per day. Mirtazapine is not approved for use in children or adolescents under 18 years old.

Specific Patient Populations:
- Geriatric patients: Dose adjustments may be necessary due to altered pharmacokinetics and increased sensitivity to sedative effects.
- Hepatic impairment: Clearance may be reduced; careful dose titration and monitoring are advised.
- Renal impairment: No specific dose adjustments are generally required, but caution is indicated in severe renal dysfunction.
- Patients with phenylketonuria should avoid the orally disintegrating tablet formulation as it contains phenylalanine.

Clinical guidelines emphasize administering mirtazapine once daily, preferably at bedtime, owing to its sedative properties which may benefit patients with concomitant insomnia.

Mechanism Of Action

Mirtazapine is classified as a tetracyclic antidepressant and exhibits a unique pharmacological profile that differentiates it from selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Its primary molecular mechanism involves antagonism of central presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, which results in enhanced noradrenergic and serotonergic neurotransmission. By blocking these inhibitory receptors, mirtazapine disinhibits the release of norepinephrine and serotonin, thereby increasing their availability in the synaptic cleft.

Additionally, mirtazapine acts as a potent antagonist of specific serotonin receptors, including 5-HT2 and 5-HT3 subtypes. This selective receptor blockade contributes to its antidepressant efficacy while reducing common serotonergic side effects such as nausea and sexual dysfunction, which are mediated via these receptors. The blockage of 5-HT2 receptors is also implicated in anxiolytic effects and improved sleep architecture.

At the cellular level, mirtazapine’s sedative and anxiolytic properties are partially attributed to its strong antagonism of histamine H1 receptors. This antihistaminergic activity causes sedation, which can be therapeutically advantageous in depressed patients experiencing insomnia. However, it also leads to side effects such as drowsiness and weight gain through increased appetite stimulation.

Clinical studies have demonstrated that mirtazapine's dual action on noradrenergic and serotonergic systems results in rapid onset of antidepressant effects in some patients compared to traditional SSRIs. Compared to other antidepressants, mirtazapine's mechanism results in a distinct side effect profile and therapeutic benefits, particularly in depressed patients with comorbid anxiety and sleep disturbances.

Pharmacological Actions

Antagonism of central presynaptic alpha-2 adrenergic receptors, increasing norepinephrine and serotonin release.
Selective antagonism of postsynaptic serotonin 5-HT2 and 5-HT3 receptors, modulating serotonergic neurotransmission.
Strong histamine H1 receptor antagonism producing sedative and anxiolytic effects.
Minimal anticholinergic activity, resulting in fewer typical anticholinergic side effects compared to TCAs.
Modulation of noradrenergic and serotonergic pathways contributing to antidepressant action.
Enhancement of neurotransmitter release improving mood, anxiety symptoms, and sleep quality.
Reduction in nausea and sexual dysfunction through selective serotonin receptor blockade.
Improvement in sleep architecture and decreased sleep latency due to antihistaminergic properties.
Potential weight gain through appetite stimulation mediated by H1 receptor antagonism.
No significant inhibition of monoamine reuptake transporters, differentiating from SSRIs and SNRIs.
Rapid onset of antidepressant effect relative to some other antidepressant classes.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of depressive symptoms with associated anxiety.
Off-label use for insomnia due to sedative properties.
Adjunct therapy in patients with depression exhibiting poor sleep quality.
Potential use in patients intolerant to SSRIs due to side effect profile.
Treatment of depression in patients with comorbid anxiety disorders.
Improvement in appetite and weight gain in patients with depression-associated anorexia.
Management of treatment-resistant depression in combination with other antidepressants (off-label).

Side Or Adverse Effects

Sedation and drowsiness, especially during treatment initiation.
Increased appetite leading to weight gain.
Dizziness and potential orthostatic hypotension.
Dry mouth.
Constipation.
Rare occurrences of agranulocytosis or other blood dyscrasias.
Potential for low sodium levels (hyponatremia) especially in elderly patients.
Serotonin syndrome when combined with other serotonergic agents.
Rare but serious hypersensitivity reactions including rash, Stevens-Johnson syndrome.
Elevated cholesterol and triglycerides in some patients.
Increased risk of suicidal thoughts and behaviors in young adults and adolescents.
Confusion or agitation in sensitive individuals.
Blurred vision.
Headache.
Seizures (rare).

Precautions

Use cautiously in patients with a history of low white blood cell counts or hematologic disorders.
Monitor closely in patients with hepatic or renal impairment.
Avoid abrupt discontinuation to prevent withdrawal symptoms such as dizziness, agitation, and electric shock sensations.
Use with caution in patients with bipolar disorder due to risk of inducing mania or hypomania.
Monitor sodium levels in elderly patients or those predisposed to hyponatremia.
Exercise caution in patients with glaucoma due to potential for increased intraocular pressure.
Assess risk-benefit in patients with cardiac diseases such as long QT syndrome.
Limit concurrent use with CNS depressants or alcohol due to additive sedative effects.
Watch for signs of serotonin syndrome when used concomitantly with serotonergic drugs.
In pregnancy, consider potential risks versus benefits as data on safety is limited.
Avoid use in children and adolescents under 18 years of age.
Caution when used with other medications metabolized by CYP450 enzymes due to potential drug interactions.
Monitor lipid profiles during long-term therapy.
Patients with phenylketonuria should avoid orally disintegrating tablets due to phenylalanine content.
Careful dose titration recommended to reduce adverse effects.

Warnings

Do not use within 14 days of MAO inhibitor therapy due to risk of severe, potentially fatal drug interactions.
Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults during initial treatment period.
Potential for serotonin syndrome, particularly when combined with other serotonergic agents.
May impair mental alertness and reaction times; avoid driving or operating machinery until individual response is known.
Avoid concomitant use with tryptophan due to risk of adverse interactions.
Risk of agranulocytosis necessitates prompt evaluation if signs of infection or low white blood cell count arise.
Alcohol potentiates CNS depressive effects and should be avoided.
Sudden discontinuation can result in withdrawal symptoms including dizziness, agitation, confusion, and electric shock-like sensations.
Risk of severe skin reactions including Stevens-Johnson syndrome or toxic epidermal necrolysis (rare).
Use caution in patients with bipolar disorder due to risk of inducing manic episodes.

Contraindication

Hypersensitivity to mirtazapine or any component of the formulation.
Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs).
Use with tryptophan or L-tryptophan.
Known history of agranulocytosis associated with mirtazapine.
Use in pediatric patients under 18 years of age (not approved).
Patients with phenylketonuria should avoid orally disintegrating tablet formulation.
Severe hepatic impairment (relative contraindication; caution required).
Patients with untreated or uncontrolled narrow-angle glaucoma (due to anticholinergic effects).

Drug Interactions

Additive central nervous system depression with opioids, benzodiazepines, muscle relaxants, and alcohol.
Potential for serotonin syndrome when combined with other serotonergic drugs such as SSRIs, SNRIs, triptans, tramadol, lithium.
Increased mirtazapine plasma levels with CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir.
Decreased mirtazapine plasma concentrations with CYP450 inducers such as rifampin, carbamazepine, and phenytoin.
Pharmacodynamic interactions with other antidepressants, antipsychotics, or mood stabilizers.
Caution with concomitant use of St. John's wort due to risk of serotonin syndrome.
Potential enhanced sedative effects when combined with other CNS depressants.
Avoid concurrent use with MAO inhibitors and methylene blue.
Cimetidine may increase mirtazapine levels by inhibiting metabolism.
Diazepam may have additive sedative properties when used with mirtazapine.
Triptans (e.g. sumatriptan, rizatriptan) may increase risk of serotonin syndrome.
Use caution when co-administered with lithium or antipsychotics due to enhanced dopaminergic or serotonergic effects.
Monitoring recommended when used with anticonvulsants such as carbamazepine or phenytoin due to enzyme induction effects.
Co-administration with drugs affecting cytochrome P450 enzymes can alter mirtazapine pharmacokinetics.

Preparations Of The Drug

Remeron Tablets: Conventional oral tablets available in 7.5 mg, 15 mg, 30 mg, and 45 mg strengths.
Remeron SolTab: Orally disintegrating tablets available in 15 mg, 30 mg, and 45 mg doses, designed for administration without water.
Both formulations intended for once-daily dosing, preferably at bedtime.
Tablets are film-coated and intended for swallowing whole.
Orally disintegrating tablets should be removed from blister packaging immediately before use and placed on the tongue to dissolve without chewing.
Storage recommended at controlled room temperature, protected from moisture, heat, and light.
Packaging typically includes blister packs to maintain stability of formulations.
No intravenous or parenteral forms are commercially available.
Extended or sustained-release forms are not available; dosing is based on immediate-release formulations.